Delivery Order SPE2DB22D1103-SPE2DB25FH1M7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $22,005.93 to AmerisourceBergen Drug Corp for the supply of Fingolimod 0.5 mg capsules (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Fingolimod is a disease-modifying therapy used in the treatment of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Fingolimod 0.5 mg capsules (30-count units) with a ceiling value of $1,497.86. This competitive, non-set-aside award was executed on August 19, 2025, with an ultimate completion date of August 20, 2025, utilizing firm fixed-price pricing. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Fingolimod 0.5 mg capsules (30-count units) with a ceiling value of $9,867.80 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of August 8, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a $5,394.00 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Fingolimod 0.5 mg capsules (30-count packages). This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion pharmaceutical prime vendor agreement running through December 2026. The award was made on a firm fixed-price basis with no set-aside designation,...
- The Defense Logistics Agency awarded a $10,360.75 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Fingolimod 0.5 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 22, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- This is a $31,944.09 firm fixed price delivery order contract awarded by the Defense Logistics Agency to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of FINGOLIMOD 0.5MG 30S medication. The contract has an ultimate completion date of July 2, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, which serves as a comprehensive global pharmaceutical support...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,811.90, is for the delivery of Fingolimod 0.5 mg capsules. The contract is a firm fixed-price delivery order, with an ultimate completion date of April 21, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This is a $37,915.66 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of FINGOLIMOD 0.5MG 30S medication. The contract has an ultimate completion date of July 1, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical...
- This is a $34,870.33 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of FINGOLIMOD 0.5 MG CAPSULE 30S, a medication used to treat multiple sclerosis. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $20,909.20, is for the delivery of FINGOLIMOD 0.5 MG CAPSULE 30S, a medication used to treat certain types of multiple sclerosis. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH1M7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $17,530.56 to AmerisourceBergen Drug Corp for the supply of Fingolimod 0.5 mg capsules (30-count packaging). This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is scheduled for completion by September 4, 2025, just one day after the award date of September 3, 2025. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare systems globally. Fingolimod is a neurological medication used to treat multiple sclerosis, reflecting the company's extensive portfolio of specialty pharmaceuticals delivered to federal medical procurement needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.5k | 9/3/25 |